- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- NNC0662-0419, Placebo, Semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 23
- States / cities
- Lancaster, California • Lomita, California • Long Beach, California + 20 more
Therapy Directory
Semaglutide clinical trials
Directory of U.S. ClinicalTrials.gov public records that list Semaglutide as a study intervention. Browse Semaglutide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
137
Shown on this page
12
Local indexed summaries
137
Local recruiting
34
Showing 1–12 of 137 matching trials for Semaglutide.
Indexed local directory records.
Top conditions
Top sponsors
Top locations
Indexed official records
Open in full search- Conditions
- Alcohol Use Disorder, Bariatric Surgery Patients, Weight Loss
- Interventions
- Semaglutide 1.0 mg
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Addiction, Alcohol Use Disorder
- Interventions
- Semaglutide, Take Control
- Drug · Behavioral
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
- Interventions
- Semaglutide
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Obesity
- Interventions
- KAI-9531, Placebo, Semaglutide
- Drug
- Lead sponsor
- Kailera
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 25
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 22 more
- Conditions
- Cardiovascular, Menopause, Menopause Hot Flashes, Menopause Related Conditions
- Interventions
- Anti-hypertensives, Fezolinetant, Hormonal therapy, Life style intervention, Lipid Lowering Medication, Metformin, semaglutide
- Drug · Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 45 Years to 55 Years · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Alcohol, Cardiovascular Disease Prevention, HIV, Smoking Cigarette
- Interventions
- Placebo, Semaglutide (Rybelsus®)
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease, Obesity, Pulmonary Hypertension, Sarcoidosis, Pulmonary
- Interventions
- Semaglutide Pen Injector
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Spinal Cord Injuries, Type 2 Diabetes
- Interventions
- Placebo, Semaglutide Injectable Product
- Other · Drug
- Lead sponsor
- Marzieh Salehi
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
- Conditions
- Genetic Predisposition, Metabolic Diseases, Type 2 Diabetes
- Interventions
- Mixed Meal Tolerance Test (MMTT), oral semaglutide
- Other · Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Obesity, Overweight
- Interventions
- Cagrilintide, Placebo cagrilintide, Placebo semaglutide, Semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 34
- States / cities
- Escondido, California • Hollywood, Florida • Jacksonville, Florida + 29 more
- Conditions
- Autonomous Cortisol Secretion (ACS), Mild Autonomous Cortisol Excess, Mild Autonomous Cortisol Secretion (MACS), Subclinical Cushing's
- Interventions
- Intervention 1: Adrenalectomy, Intervention 2: Semaglutide
- Procedure · Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Dallas, Texas
About this Semaglutide clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Semaglutide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
- How to narrow results
- Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Semaglutide.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Semaglutide.